NERLYNX: Major Growth Driver for PBYI
Puma Biotechnology (PBYI) reported net sales of $52.6 million for NERLYNX in the third quarter, which is higher than its revenues of $50.8 million reported in the second quarter. According to the company’s third-quarter earnings conference call, Puma Biotechnology has attributed the growth to an increase in the number of patients being prescribed NERLYNX and patients choosing to stay on the therapy.